Aspen Neuroscience, Inc.(NasdaqGS: ASPE) added to NASDAQ Composite Index

Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company. The Company is focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with unmet medical need. Its lead product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy being evaluated for the treatment of Parkinson's disease (PD). It has the potential to be disease-modified by primarily replacing a patient's lost dopaminergic (DA) neurons with dopaminergic neuron precursor cells (DANPCs). The Company is leveraging its proprietary platform to build a diversified pipeline of autologous iPSC-based therapies for the treatment of multiple CNS diseases, with an initial focus on sporadic and genetic PD. The Company is also conducting the open-label Phase 1/2a ASPIRO trial of a single dose of sasineprocel in mid-stage to moderately advanced PD patients.